Benzinga

Benzinga

Benzinga

viernes, agosto 28

TG Therapeutics Inc

TGTXNASDAQ
Trade with Public
Trade with Public
$55.72
0.691.25%
al cierre: Aug 27, 5:00 PM EST
$55.41
-0.31-0.56%
After hour: 6:58 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

TG Therapeutics Financials

TG Therapeutics (TGTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M Est

TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $925.000 million to $950.000 million vs $942.370 million estimate.
Benzinga Newsdesk

PRO
TG Therapeutics Q2 EPS $0.05 Misses $0.33 Estimate, Sales $240.335M Beat $229.721M Estimate

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.33 by 84.85 percent. This is a 70.59 percent decrease over earnings of $0.17 per share from
Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
TG Therapeutics Q1 Adj. EPS $0.18 Misses $0.30 Estimate, Sales $204.918M Beat $196.814M Estimate

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.30 by 40 percent. This is a 500 percent increase over earnings of $0.03 per share from the
Benzinga Newsdesk

PRO
TG Therapeutics Raises FY2026 Sales Guidance from $875.000M-$900.000M to $925.000M vs $906.021M Est

TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $875.000 million-$900.000 million to $925.000 million vs $906.021 million estimate.
Benzinga Newsdesk

TG Therapeutics Q4 Earnings Assessment

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved